(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Thursday maintained an optimistic outlook for the year ahead, despite seeing annual revenue fall. Read More
(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates. Read More
(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Thursday said that its LYT-200 cancer treatment has received a significant endorsement from the US drugs regulator. Read More
(Alliance News) - PureTech Health PLC on Tuesday said its founding chief executive officer, Daphne Zohar, will shift to become CEO of Seaport Therapeutics, a biopharmaceutical company founded by PureTech. Read More
(Alliance News) - Blue-chip stock prices in Europe closed higher on Tuesday, showing little signs of nerves ahead of Wednesday's Federal Reserve decision and UK inflation reading. Read More
(Alliance News) - PureTech Health PLC on Tuesday said it plans to return USD100 million to shareholders with a tender offer, starting after it publishes its annual report in April. Read More
(Alliance News) - PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration. Read More
(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan. Read More
(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come. Read More
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News: Read More
PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease. Read More
(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell. Read More
(Alliance News) - PureTech Health PLC on Tuesday said its therapeutic LYT-300 achieved its primary endpoint for acute anxiety reduction, in a Phase 2a trial using healthy volunteers. Read More
PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage. Read More
(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment. Read More
(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More